Order Article Reprints

Aguirre-Ruiz P, Ariceta B, Viguria MC, Zudaire MT, Blasco-Iturri Z, Arnedo P, Aguilera-Diaz A, Jauregui A, Mañú A, Prosper F, et al. Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms. Journal of Clinical Medicine. 2020; 9(12):3818. https://doi.org/10.3390/jcm9123818

Aguirre-Ruiz, Paula, Beñat Ariceta, María Cruz Viguria, María Teresa Zudaire, Zuriñe Blasco-Iturri, Patricia Arnedo, Almudena Aguilera-Diaz, Axier Jauregui, Amagoia Mañú, Felipe Prosper, and et al. 2020. "Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms" Journal of Clinical Medicine 9, no. 12: 3818. https://doi.org/10.3390/jcm9123818

Aguirre-Ruiz, P., Ariceta, B., Viguria, M. C., Zudaire, M. T., Blasco-Iturri, Z., Arnedo, P., Aguilera-Diaz, A., Jauregui, A., Mañú, A., Prosper, F., Mateos, M. C., Fernández-Mercado, M., Larráyoz, M. J., Redondo, M., Calasanz, M. J., Vázquez, I., & Bandrés, E. (2020). Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms. Journal of Clinical Medicine, 9(12), 3818. https://doi.org/10.3390/jcm9123818